Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020)

What is it about?

An International Taskforce used a consensus-building process to address questions related to the acute management of COVID-19 pneumonia, as well as the post-discharge management of COVID-19 survivors. The Taskforce made consensus suggestions for remdesivir and dexamethasone in patients with acute COVID-19 pneumonia who require oxygen support, but against hydroxychloroquine except in a clinical trial. It also made a consensus suggestion for 3 months of therapeutic-dose anticoagulant therapy in COVID-19 patients with confirmed venous thromboembolism. There was insufficient agreement to make consensus suggestions related to the post-discharge management of COVID-19 survivors, thereby identifying this topic as a research priority.

Featured Image